WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

ATC alterations from 2005-2024

Cumulative overview of all ATC alterations performed in the period 2005-2024. The year changed is when the alterations were implemented in the ATC/DDD Index.

Previous ATC codeSubstance nameNew ATC codeYear changed
N05CM21lemborexantN05CJ022024
N05CM19suvorexantN05CJ012024
L04AA59avacopanL04AJ052024
L04AA57ublituximabL04AG142024
L04AA56deucravacitinibL04AF072024
L04AA55sutimlimabL04AJ042024
L04AA54pegcetacoplanL04AJ032024
L04AA53teprotumumabL04AG132024
L04AA52ofatumumabL04AG122024
L04AA51anifrolumabL04AG112024
L04AA50ponesimodL04AE042024
L04AA49peficitinibL04AF062024
L04AA47inebilizumabL04AG102024
L04AA46itacitinibL04AF052024
L04AA45filgotinibL04AF042024
L04AA44upadacitinibL04AF032024
L04AA43ravulizumab L04AJ022024
L04AA42siponimodL04AE032024
L04AA39emapalumabL04AG092024
L04AA38ozanimodL04AE022024
L04AA37baricitinibL04AF022024
L04AA36ocrelizumabL04AG082024
L04AA35begelomabL04AG072024
L04AA34alemtuzumabL04AG062024
L04AA33vedolizumabL04AG052024
L04AA31teriflunomideL04AK022024
L04AA29tofacitinibL04AF012024
L04AA27fingolimodL04AE012024
L04AA26belimumabL04AG042024
L04AA25eculizumabL04AJ012024
L04AA23natalizumabL04AG032024
L04AA21efalizumabL04AG022024
L04AA18everolimusL04AH022024
L04AA13leflunomideL04AK012024
L04AA10sirolimusL04AH012024
L04AA02muromonab-CD3L04AG012024
L01XY03nivolumab and relatlimabL01FY022024
L01XY02pertuzumab and trastuzumabL01FY012024
N03AX16pregabalinN02BF02 2023
N03AX12gabapentin N02BF01 2023
N02BG11mirogabalin N02BF03 2023
L01XX71 tisagenlecleucel L01XL042023
L01XX70axicabtagene ciloleucelL01XL032023
L01XX51 talimogene laherparepvecL01XL022023
L01XX37sitimagene ceradenovecL01XL012023
J07BX03covid-19 vaccinesdeleted2023
L01XC42prolgolimabL01FF082022
L01XC41trastuzumab deruxtecanL01FD042022
L01XC40dostarlimabL01FF072022
L01XC39belantamab mafodotinL01FX152022
L01XC38isatuximabL01FC022022
L01XC37polatuzumab vedotinL01FX142022
L01XC36enfortumab vedotinL01FX132022
L01XC35tafasitamabL01FX122022
L01XC34moxetumomab pasudotoxL01FB022022
L01XC33cemiplimabL01FF062022
L01XC32atezolizumabL01FF052022
L01XC31avelumabL01FF042022
L01XC29bermekimabL01FX112022
L01XC28durvalumabL01FF032022
L01XC27olaratumabL01FX102022
L01XC26inotuzumab ozogamicinL01FB012022
L01XC25mogamulizumabL01FX092022
L01XC24daratumumabL01FC012022
L01XC23elotuzumabL01FX082022
L01XC22necitumumabL01FE032022
L01XC21ramucirumabL01FG022022
L01XC19blinatumomabL01FX072022
L01XC18pembrolizumabL01FF022022
L01XC17nivolumabL01FF012022
L01XC16dinutuximab betaL01FX062022
L01XC15obinutuzumabL01FA032022
L01XC14trastuzumab emtansineL01FD032022
L01XC13pertuzumabL01FD022022
L01XC12brentuximab vedotinL01FX052022
L01XC11ipilimumabL01FX042022
L01XC10ofatumumabL01FA022022
L01XC09catumaxomabL01FX032022
L01XC08panitumumabL01FE022022
L01XC07bevacizumabL01FG012022
L01XC06cetuximabL01FE012022
L01XC05gemtuzumab ozogamicinL01FX022022
L01XC03trastuzumabL01FD012022
L01XC02rituximabL01FA012022
L01XC01edrecolomabL01FX012022
L01EX20pemigatinibL01EN022022
L01EX16erdafitinibL01EN012022
J06BB22obiltoxaximabJ06BC042022
J06BB21bezlotoxumabJ06BC032022
J06BB18raxibacumabJ06BC022022
J06BB17motavizumabJ06BD022022
J06BB16palivizumabJ06BD012022
L01XX68belotecanL01CE042021
L01XX65alpelisibL01EM032021
L01XX64entinostatL01XH052021
L01XX63glasdegibL01XJ032021
L01XX61copanlisibL01EM022021
L01XX60talazoparibL01XK042021
L01XX56etirinotecan pegol L01CE032021
L01XX55rucaparib L01XK032021
L01XX54niraparib L01XK022021
L01XX50ixazomib L01XG032021
L01XX49belinostatL01XH042021
L01XX48sonidegibL01XJ022021
L01XX47idelalisibL01EM012021
L01XX46olaparibL01XK012021
L01XX45carfilzomibL01XG022021
L01XX43vismodegibL01XJ012021
L01XX42panobinostatL01XH032021
L01XX39romidepsinL01XH022021
L01XX38vorinostatL01XH012021
L01XX32bortezomibL01XG012021
L01XX25bexaroteneL01XF032021
L01XX22alitretinoinL01XF022021
L01XX19irinotecanL01CE022021
L01XX17topotecanL01CE012021
L01XX14tretinoinL01XF012021
L01XE57fedratinibL01EJ022021
L01XE56entrectinibL01EX142021
L01XE54gilteritinibL01EX132021
L01XE53larotrectinibL01EX122021
L01XE52quizartinibL01EX112021
L01XE51acalabrutinibL01EL022021
L01XE50abemaciclibL01EF032021
L01XE48icotinibL01EB082021
L01XE47dacomitinibL01EB072021
L01XE46encorafenibL01EC032021
L01XE45neratinibL01EH022021
L01XE44lorlatinibL01ED052021
L01XE43brigatinibL01ED042021
L01XE42ribociclibL01EF022021
L01XE41binimetinibL01EE032021
L01XE40olmutinibL01EB062021
L01XE39midostaurinL01EX102021
L01XE38cobimetinibL01EE022021
L01XE37rociletinibL01EB052021
L01XE36alectinibL01ED032021
L01XE35osimertinibL01EB042021
L01XE34tivozanibL01EK032021
L01XE33palbociclibL01EF012021
L01XE32cediranibL01EK022021
L01XE31nintedanibL01EX092021
L01XE29lenvatinibL01EX082021
L01XE28ceritinibL01ED022021
L01XE27ibrutinibL01EL012021
L01XE26cabozantinibL01EX072021
L01XE25trametinibL01EE012021
L01XE24ponatinibL01EA052021
L01XE23dabrafenibL01EC022021
L01XE22masitinibL01EX062021
L01XE21regorafenibL01EX052021
L01XE19ridaforolimusL01EG032021
L01XE18ruxolitinibL01EJ012021
L01XE17axitinibL01EK012021
L01XE16crizotinib L01ED012021
L01XE15vemurafenibL01EC012021
L01XE14bosutinibL01EA042021
L01XE13afatinibL01EB032021
L01XE12vandetanibL01EX042021
L01XE11pazopanibL01EX032021
L01XE10everolimusL01EG022021
L01XE09temsirolimusL01EG012021
L01XE08nilotinibL01EA032021
L01XE07lapatinibL01EH012021
L01XE06dasatinibL01EA022021
L01XE05sorafenibL01EX022021
L01XE04sunitinibL01EX012021
L01XE03erlotinibL01EB022021
L01XE02gefitinibL01EB012021
L01XE01imatinibL01EA012021
J05AX12dolutegravirJ05AJ032021
J05AX11elvitegravirJ05AJ022021
J05AX08raltegravirJ05AJ012021
N02CX08galcanezumabN02CD022020
N02CX07erenumabN02CD012020
L01XX09miltefosineP01CX042020
N07XX09dimethyl fumarateL04AX072019
J05AX69sofosbuvir and velpatasvirJ05AP552018
J05AX68elbasvir and grazoprevir J05AP542018
J05AX67ombitasvir, paritaprevir and ritonavir J05AP532018
J05AX66dasabuvir, ombitasvir, paritaprevir and ritonavir J05AP522018
J05AX65sofosbuvir and ledipasvirJ05AP512018
J05AX16dasabuvirJ05AP092018
J05AX15sofosbuvirJ05AP082018
J05AX14daclatasvirJ05AP072018
J05AE15asunaprevirJ05AP062018
J05AE14simeprevir J05AP052018
J05AE13faldaprevirJ05AP042018
J05AE12boceprevirJ05AP032018
J05AE11telaprevirJ05AP022018
J05AB04ribavirinJ05AP012018
J01DD54 29)ceftriaxone, combinationsJ01DD632018
H01BA06argipressinH01BA01 28)2018
A01AD02 27)benzydamine R02AX032018
R05CB12tioproninG04BX162017
N02BE51 25)oxycodone and paracetamol N02AJ172017
N02BE51 25)codeine and other non-opioid analgesics N02AJ092017
N02BE51 25)codeine and paracetamol N02AJ062017
N02BE51 24)dihydrocodeine and paracetamol N02AJ012017
N02BA51 24)oxycodone and acetylsalicylic acidN02AJ182017
N02BA51 24)codeine and acetylsalicylic acidN02AJ072017
N02BA51 24)dihydrocodeine and acetylsalicylic acidN02AJ022017
N02AX52 20)tramadol and paracetamolN02AJ132017
N02AA59 23)codeine and other non-opioid analgesics N02AJ092017
N02AA59 23)codeine and ibuprofenN02AJ082017
N02AA59 23)codeine and acetylsalicylic acid N02AJ072017
N02AA59 23)codeine and paracetamolN02AJ062017
N02AA58 22)dihydrocodeine and other non-opioid analgesicsN02AJ032017
N02AA58 22)dihydrocodeine and acetylsalicylic acid N02AJ022017
N02AA58 22)dihydrocodeine and paracetamol N02AJ012017
N02AA55 21)oxycodone and ibuprofenN02AJ192017
N02AA55 21)oxycodone and acetylsalicylic acidN02AJ182017
N02AA55 21)oxycodone and paracetamolN02AJ172017
M01AE51 19)codeine and ibuprofenN02AJ082017
M01AE51 19)dihydrocodeine and other non-opioid analgesicsN02AJ032017
L04AC06mepolizumabR03DX092017
L01BA01 13)methotrexateL04AX032017
C07FB02 18)metoprolol and amlodipine C07FB132017
C07FB02 18)metoprolol and felodipineC07FB022017
C07FA05propranolol and other combinations 17)C07FX012017
C07AB57bisoprolol and acetylsalicylic acid 16)C07FX042017
C07AB52metoprolol and acetylsalicylic acid  15)C07FX032017
C07AA57sotalol and acetylsalicylic acid  14) C07FX022017
B02BD12trenonacog alfaB02BD04 12) 2017
B02BD09nonacog alfaB02BD04 12) 2017
A10BX14dulaglutideA10BJ052017
A10BX13albiglutideA10BJ042017
A10BX12empagliflozinA10BK032017
A10BX11canagliflozinA10BK022017
A10BX10lixisenatideA10BJ032017
A10BX09dapagliflozinA10BK012017
A10BX07liraglutideA10BJ022017
A10BX04exenatideA10BJ012017
B03AB06ferric citrateV03AE082016
A12AA12calcium acetate 11)V03AE072016
L01XC04alemtuzumabL04AA342015
R03AK07 10)formoterol and mometasoneR03AK092014
R03AK07 10)formoterol and beclometasoneR03AK082014
R03AK04 9)salbutamol and ipratropium bromideR03AL022014
R03AK03fenoterol and ipratropium bromide 8)R03AL012014
B06AA11bromelainsD03BA032014
B03AC07ferric sodium gluconate complexB03AC 7)2014
B03AC06ferric oxide dextran complexesB03AC 7)2014
B03AC05ferric sorbitol gluconic acid complexB03AC 7)2014
B03AC03iron-sorbitol-citric acid complexB03AC 7)2014
B03AC02saccharated iron oxideB03AC 7)2014
B03AC01ferric oxide polymaltose complexesB03AC 7)2014
B02BC10fibrinogen, humanB02BC30 6)2014
S01AX23besifloxacinS01AE082013
S01AX22moxifloxacinS01AE072013
S01AX21gatifloxacinS01AE062013
S01AX19levofloxacinS01AE052013
S01AX17lomefloxacinS01AE042013
S01AX13ciprofloxacinS01AE032013
S01AX12norfloxacinS01AE022013
S01AX11ofloxacinS01AE012013
N02AA09diamorphineN07BC062013
N01AX01droperidolN05AD08 (existing code)2013
J05AE06lopinavir and ritonavirJ05AR102013
H01CA03histrelinL02AE052013
B01AX06rivaroxabanB01AF012013
A03AE04prucaloprideA06AX052013
A03AE02tegaserodA06AX062013
D11AX19alitretinoinD11AH042012
C01EB19icatibantB06AC022012
B02AB03 5)c1-inhibitor, plasma derivedB06AC012012
R03CA02ephedrineC01CA26 4)2011
P01BE52artemether and lumefantrine 26)P01BF012011
G04BE05phentolamineV03AB362011
G03AC03levonorgestrelG03AD01 3)2011
N05AX09clotiapineN05AH062010
D11AX17cromoglicic acidD11AH032010
D11AX15pimecrolimusD11AH022010
D11AX14tacrolimusD11AH012010
A11CC07paricalcitol H05BX022010
N07BA02bupropionN06AX122009
N01AB03methoxyfluraneN02BG092009
C10AX04benfluorexA10BX062009
C01EB12tedisamilC01BD062009
N05CM17melatoninN05CH012008
N05AK01tetrabenazineN07XX062008
L04AA17adalimumabL04AB042008
L04AA16afelimomabL04AB032008
L04AA14anakinraL04AC032008
L04AA12infliximabL04AB022008
L04AA11etanerceptL04AB012008
L04AA09basiliximabL04AC022008
L04AA08daclizumabL04AC012008
L04AA05tacrolimusL04AD022008
L04AA01ciclosporinL04AD012008
G03DC05tiboloneG03CX012008
D03AX08isosorbide dinitrateC05AE022008
D03AX07glyceryl trinitrateC05AE012008
S01XA17pegaptanibS01LA032007
S01XA16anecortaveS01LA022007
L01XX34erlotinibL01XE032007
L01XX31gefitinibL01XE022007
L01XX28imatinibL01XE012007
L01XD02verteporfinS01LA012007
J05AF30combinationsJ05AR 2)2007
J05AB54ribavirin, combinationsL03AB60 1)2007
C10AA55atorvastatin, combinationsC10BX032006
C10AA53pravastatin, combinationsC10BX022006
C10AA52lovastatin, combinationsC10BA012006
C10AA51simvastatin, combinationsC10BX012006
C04AX13piribedilN04BC082006
B01AC14anagrelideL01XX352006
V09AX02fludeoxyglucose [18F]V09IX042005
J01DA63ceftriaxone, combinationsJ01DD542005
J01DA42cefdinirJ01DD152005
J01DA41cefprozilJ01DC102005
J01DA40cefmetazoleJ01DC092005
J01DA39ceftibutenJ01DD142005
J01DA38loracarbefJ01DC082005
J01DA37cefpiromeJ01DE022005
J01DA36ceftezoleJ01DB122005
J01DA35cefroxadineJ01DB112005
J01DA34cefacetrileJ01DB102005
J01DA33cefpodoximeJ01DD132005
J01DA32cefoperazoneJ01DD122005
J01DA31cefradineJ01DB092005
J01DA30cefapirinJ01DB082005
J01DA27cefpiramideJ01DD112005
J01DA26cefetametJ01DD102005
J01DA25cefodizimeJ01DD092005
J01DA24cefepimeJ01DE012005
J01DA23cefiximeJ01DD082005
J01DA22ceftizoximeJ01DD072005
J01DA21cefatrizineJ01DB072005
J01DA19cefotiamJ01DC072005
J01DA18latamoxefJ01DD062005
J01DA17cefonicidJ01DC062005
J01DA16cefmenoximeJ01DD052005
J01DA15cefazedoneJ01DB062005
J01DA14cefotetanJ01DC052005
J01DA13ceftriaxoneJ01DD042005
J01DA12cefsulodinJ01DD032005
J01DA11ceftazidimeJ01DD022005
J01DA10cefotaximeJ01DD012005
J01DA09cefadroxilJ01DB052005
J01DA08cefaclorJ01DC042005
J01DA07cefamandoleJ01DC032005
J01DA06cefuroximeJ01DC022005
J01DA05cefoxitinJ01DC012005
J01DA04cefazolinJ01DB042005
J01DA03cefalotinJ01DB032005
J01DA02cefaloridineJ01DB022005
J01DA01cefalexinJ01DB012005
1) ATC level name changed to: peginterferon-alfa-2b, combinations
2) Separate ATC 5th levels are established for the different combinations in ATC-gr J05AR Antivirals for treatment of HIV infections, combinations
3) Oral products (packages) only indicated for emergency contraception.
4) Only parenteral formulations.
5) New ATC 5th level name
6) Combinations previously classified in B02BC10 should be altered to B02BC30 combinations (existing code).
7) ATC 5th levels deleted, all products classified on the 4th level only (B03AC Iron, parenteral preparations). The DDD remains unchanged, 0.1 g (P) Fe.
8) Previous ATC level name: fenoterol and other drugs for obstructive airway diseases.
9) Split of code. Combinations of salbutamol and sodium cromoglicate remains in R03AK04.
10) Split of code. Combinations of formoterol and budesonide remains in R03AK07.
11) Previous ATC level name: calcium acetate anhydrous
12) All coagulation factor IX products are classified in ATC code B02BD04.
13) Split of ATC code. Only the classification of pre-filled syringe/pen of methotrexate for use in non-cancer indications is changed. Parenteral products used for treatment of cancer will remain in L01BA01.
14) ATC level name changed from: sotalol, combinations 
15) ATC level name changed from: metoprolol, combinations 
16) ATC level name changed from: bisoprolol, combinations 
17) ATC level name changed from: propranolol and other antihypertensives 
18) Split of ATC code. ATC level name changed from: metoprolol and other antihypertensives. Combinations of metoprolol and felodipine remains in C07FB02.
19) Split of ATC code. The different fixed combinations of ibuprofen and opioid analgesics are given new ATC 5th levels in N02AJ Opioids and non-opioid analgesics. M01AE51 ibuprofen, combinations remains for other combinations.
20) Split of ATC code. ATC level name changed from: tramadol, combinations. The different fixed combinations of tramadol and other analgesics are given new ATC 5th levels in N02AJ Opioids and non-opioid analgesics.
21) Split of ATC code. ATC level name changed from: oxycodone, combinations. The different fixed combinations of oxycodone and other analgesics are given new ATC 5th levels in N02AJ Opioids and non-opioid analgesics. ATC code N02AA55 remains for combinations of oxycodone and naloxone (changed level name).
22) Split of ATC code. The different fixed combinations of dihydrocodeine and other analgesics are given new ATC 5th levels in N02AJ Opioids and non-opioid analgesics. ATC code N02AA58 dihydrocodeine, combinations is maintained for other combinations.
23) Split of ATC code. The different fixed combinations of codeine and other analgesics are given new ATC 5th levels in N02AJ Opioids and non-opioid analgesics. ATC code N02AA59 codeine, combinations is maintained for other combinations.
24) Split of ATC code. The different fixed combinations of acetylsalisylic acid and opioid analgesics are given new ATC 5th levels in N02AJ Opioids and non-opioid analgesics. ATC code N02BA51 acetylsalicylic acid, combinations excl. psycholeptics is maintained for other combinations.
25) Split of ATC code. The different fixed combinations of paracetamol and opioid analgesics are given new ATC 5th levels in N02AJ Opioids and non-opioid analgesics. ATC code N02BE51 paracetamol, combinations excl. psycholeptics is maintained for other combinations.
26) New ATC 5th level name; changed from artemether, combinations (P01BE52).
27) Split of code. Alteration of ATC code applies only for benzydamine lozenges
28) New ATC level name vasopressin (argipressin)
29) Split of code. Combinations of ceftriaxone and other substances remain in J01DD54 while combinations of ceftriaxone and beta-lactamase inhibitors are moved to J01DD63 ceftriaxone and beta-lactamase inhibitor

Last updated: 2024-01-19